In fact, silencing of FGFR4 is able to reduce CRC cell viability and it has synergistic activity with 5-fluorouracil (5-FU) and oxaliplatin chemotherapy in CRC chemotherapy-refractory cell lines by decreasing the activity of STAT3 transcription factor [29]. This evidence concerns the gene STAT3 and colorectal carcinoma.